Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Congenital Heart Disease (CHD) Market Growth Performance Trended Historically, And What Lies Ahead?

The market size associated with congenital heart disease (CHD) has seen substantial growth recently. The market is expected to grow from a value of $4.42 billion in 2024 to $4.87 billion in 2025, with a compound annual growth rate (CAGR) of 10.1%. The surge that was observed during the recent years can be linked to several factors including a rise in risk elements such as obesity and smoking, advancements in diagnostic technology, the growth of the elderly population, intensified awareness initiatives, improved policies for reimbursement, and an escalation in research and development funding.

What Is the Forecast for the Congenital Heart Disease (CHD) Market Size Through 2029?

The market for congenital heart disease (CHD) is anticipated to witness solid expansion in the coming years, growing to a predicted $7.05 billion by 2029 with a compound annual growth rate (CAGR) of 9.7%. Factors contributing to this growth in the projected period include increased access to healthcare in underdeveloped areas, constant advancements in cardiac imaging technology, widespread campaigns focusing on early diagnosis and treatment, and a global increase in healthcare spending, alongside advances in personalized medicine. Key trends for the forecast period incorporate the use of minimally invasive surgical methods, the growing use of telemedicine for remote patient consultations and monitoring, increasing demand for customized treatment strategies, the emergence of innovative implantable devices featuring enhanced function and lifespan, and the incorporation of artificial intelligence and machine learning in diagnosis and treatment procedures.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15545&type=smp

What are the Key Market Players in Congenital Heart Disease (CHD) Market and How They’re Evolving?

Major companies operating in the congenital heart disease (CHD) market are Pfizer Inc., AstraZeneca Plc, Abbott Laboratories, Novartis AG, Medtronic, Siemens Healthineers, Philips Healthcare, Roche Diagnostics International Ltd., Boston Scientific Corp., Laboratory Corporation of America Holdings (LabCorp), Terumo Corporation, Mindray Medical International Limited, Canon Medical Systems Corporation, Masimo Corporation, Neusoft Corp., Carestream Health, Midmark Corporation, Contec Medical Systems, Randox Laboratories Ltd., Schiller AG, BPL Medical Technologies, Compumedics Limited, Biocare Medical, Bionet America Inc., Nasan Medical Electronics Pvt Ltd

What Are the Primary Growth Drivers in the Congenital Heart Disease (CHD) Market?

The projected rise in cases of maternal diabetes is likely to fuel the expansion of the congenital heart disease (CHD) market in the coming years. Gestational diabetes mellitus (GDM), or maternal diabetes, is the term given to diabetes that develops in women who were not previously diabetic prior to becoming pregnant. This condition is triggered by alterations in lifestyle, such as an increase in sedentary behavior and poor dietary choices, along with a rising obesity rate among women of reproductive age. The occurrence of maternal diabetes can result in newborns having congenital heart disease (CHD) since excess glucose in the mother’s blood influences the development of the child’s heart. This abnormal blood sugar level can disrupt the proper development of the fetal heart, thereby raising the chances of CHD. As an example, the National Health Service, a government department in the UK, stated in October 2023 that there was a rise from 4.9% in 2021 to 6.6% in 2022 in adverse pregnancy outcomes in women diagnosed with type 2 diabetes. Thus, the surge in maternal diabetes diagnoses is boosting the congenital heart disease (CHD) market’s growth.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=15545&type=smp

What Are the Leading Segments in the Global Congenital Heart Disease (CHD) Industry?

The congenital heart disease (CHD) market covered in this report is segmented –

1) By Type: Heart Valve Defects, Heart Wall Defects, Blood Vessel Defects, Other Types

2) By Diagnosis: Electrocardiogram, Chest X-ray,  Echocardiogram, Transesophageal Echocardiogram, Pulse Oximetry, Exercise Stress Test, Cardiac Computed Tomography (CT) Scan Or Magnetic Resonance Imaging (MRI), Cardiac Catheterization, Other Diagnosis

3) By Treatment: Interventional Cardiology, Cardiac Surgery, Telemedicine, Medication Management, Lifestyle Modifications

4) By Age Group: Infants, Children, Adolescents, Adults

5) By Application: Hospitals And Clinics, Diagnostic Centers, Ambulatory Surgical Centers, Research And Academic Institutions

Subsegments:

1) By Heart Valve Defects: Aortic Valve Stenosis, Pulmonary Valve Stenosis, Mitral Valve Prolapse, Tricuspid Valve Defects, Valve Regurgitation

2) By Heart Wall Defects: Atrial Septal Defect (ASD), Ventricular Septal Defect (VSD), Atrioventricular Septal Defect (AVSD), Hypoplastic Left Heart Syndrome (HLHS), Tetralogy of Fallot (TOF)

3) By Blood Vessel Defects: Coarctation Of The Aorta, Patent Ductus Arteriosus (PDA), Pulmonary Artery Stenosis, Transposition Of The Great Arteries (TGA), Truncus Arteriosus

4) By Other Types: Single Ventricle Defects, Ebstein’s Anomaly, Total Anomalous Pulmonary Venous Return (TAPVR), Coronary Artery Anomalies, Pulmonary Venous Obstruction

What Are the Key Market Trends in the Congenital Heart Disease (CHD) Industry?

Leading businesses in the congenital heart disease industry are innovating non-surgical heart valves to enhance patient results and life quality. Transcatheter, or non-operative heart valves, are therapeutic appliances that manage heart valve diseases without necessitating conventional open-heart surgery. For instance, Medtronic, a medical tech firm based in the US, re-launched its Harmony Transcatheter Pulmonary Valve (TPV) System in February 2023. This system is a revolutionary, minimally invasive substitute for open-heart surgery for congenital heart disease patients, particularly those with native or previously surgically remedied right ventricular outflow tract (RVOT) abnormalities. The system, which is the first FDA-approved valve for the right side, offers a non-operative resolution for patients experiencing severe pulmonary valve regurgitation. The Harmony TPV System was granted U.S. FDA approval in 2021 and was reissued after a voluntary recall, signaling Medtronic’s dedication to progressing solutions for congenital heart disease patients.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/congenital-heart-disease-chd-global-market-report

What Is the Regional Outlook for the Congenital Heart Disease (CHD) Market?

North America was the largest region in the congenital heart disease (CHD) market in 2023. The regions covered in the congenital heart disease (CHD) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15545

This Report Delivers Insight On:

1. How big is the congenital heart disease (chd) market, and how is it changing globally?

2. Who are the major companies in the congenital heart disease (chd) market, and how are they performing?

3. What are the key opportunities and risks in the congenital heart disease (chd) market right now?

4. Which products or customer segments are growing the most in the congenital heart disease (chd) market?

5. What factors are helping or slowing down the growth of the congenital heart disease (chd) market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model